AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$ALEC

Wong-Sarad Grace sold $18K of ALEC

Wong-Sarad Grace (Principal Accounting Officer) sold 9,184 shares of Alector, Inc. (ALEC) at an average of $1.94 ($1.88–$1.97) across 2 trades over 2026-06-02 to 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wong-Sarad Grace
Published Jun 3, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALEC
Bearish
medium confidence
Mentioned
$ALEC
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALECBearishLow
01

Why it matters

The disclosed sale is modest and likely reflects a scheduled liquidity event rather than new information about the company's fundamentals.

02

Market read

The filing provides a primary source of insider transaction data but is unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data releases may outweigh insider activity.

Relevance 2/10Novelty 2/10Timing: after-hours filing on 2026-06-03

Background

Alector, a clinical-stage biotech, filed a Form 4 reporting an insider's open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$ALECBearishMedium confidence
Context

Form 4 shows insider Grace Wong-Sarad sold 9,184 shares (~$18K) from a 10b5-1 plan.

Expected impact

likely modest downward pressure as market absorbs insider sale

Evidence & confidence

Sale size is small relative to float; typical for 10b5-1 plans, limited price effect.

Market effects

Sector

No broader sector impact; Alector operates in biotech niche.

Regional

Limited to US biotech investors.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

Insider sale could be routine liquidity need, not a red flag.

Key entities

  • Insider
    Wong-Sarad Grace

    Principal Accounting Officer of Alector

  • Company
    Alector, Inc.

    Biotech firm developing neurodegeneration therapies

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALEC insider trading history →

Related articles

OCT 7
MedAI 8/10

Genentech pays Alector $100m for Parkinson drug

Genentech paid Alector $100m upfront for global rights to AL050, a Parkinson's drug. Alector may receive up to $1.17b in milestones. AL050 targets GCase deficiency, a factor in Parkinson's. The deal extends Alector's cash runway to 2029, supporting other Alzheimer's and Parkinson's programs.

bioxconomy.com2 min
OCT 6
HighAI 9/10

Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion

Roche will pay up to $1.27 billion to license Alector's experimental Parkinson's therapy, AL050. The deal includes a $100 million upfront payment and potential milestone payments. Alector's shares surged 72% in premarket trading. Roche's Genentech unit will handle development and commercialization, with Alector eligible for royalties.

ksl.com2 min
OCT 5
$ALECHigh

Alector (ALEC) Shares Jump 22% on Genentech Licensing Deal for A

Alector Inc (ALEC) shares rose 22% after announcing a licensing deal with Genentech for its AL050 program. The deal includes a $100M upfront payment and potential milestone payments up to $1.17B. Alector's P/S ratio is 17.46, higher than historical and industry averages, reflecting growth expectations. The company's GF Score is 31/100, indicating weak fundamentals but some momentum.

gurufocus.com2 min